Axar.az
UP

Axar.Az Logo

The drug was created in the US at a price of 2.8 mln dollars

Home page Health
12 Punto 14 Punto 16 Punto 18 Punto

The US Food and Drug Administration has approved Zinteglo, a drug developed by the Bluebird Bio company for gene therapy of one of the rare types of anemia.

Axar.az informs that this was reported by Reuters.

"There are about 1,500 people with beta thalassemia in the United States who could start treatment with Zinteglo by the end of 2022. The price of one injection will cost 2.8 million dollars, which is enough to completely eliminate the symptoms," the information said.

Note that beta thalassemia is an inherited disease caused by several different mutations that reduce the production of hemoglobin in red blood cells.

Date
2022.08.21 / 20:55
Author
Zuleykha Aghasieva
Comments
See also

WHO warning: cases of infection will increase!

Baku to host next Global Health Summit

Türkiye's Minister of Health visits Shusha

WHO organizes expert mission to Azerbaijan

Coronavirus death toll in the world exceeded 6.5 M

The end of the corona pandemic is approaching - WHO

US registers first monkeypox virus-related death

WHO records over 41,000 monkeypox cases globally

The virus is not tired of us - WHO

Director of "Pfizer" was infected with the coronavirus

Latest
Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla
ArxivBağla